慢性疹治疗药物治疗的比较有效性和安全性:网络元分析和风险效益评估
Tian Qian1, Xia Jiang1, Daojun Zhang1
1Dermatology and Plastic Surgery Center, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Expert opinion on drug safety
|September 26, 2023
概括
与H1抗胰岛素药物相比,300mg和150mg的奥马利祖马布 (OMA) 显著改善了慢性疹 (CU) 的结果. 300mg的OMA是最优的治疗方法,150mg作为一个可行的替代方案.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 慢性疹 (CU) 是一种常见的疾病,导致经常性疹.
- 目前的治疗指南建议CU多种药物选择.
- 各种CU疗法的有效性和安全性需要进行比较分析.
研究的目的:
- 为了比较慢性疹的不同药物治疗的疗效和安全性.
- 评估应答率,减轻症状严重程度和改善生活质量.
- 为CU进行药理干预措施的风险效益评估.
主要方法:
- 一个网络元分析 (NMA) 综合了随机对照试验 (RCT) 和现实研究 (RWS) 的数据.
- 关键的结果指标包括响应率,7天内疹活动评分 (UAS7),皮肤病生命质量指数 (DLQI) 和不良事件.
- 对比的治疗方法是H1抗组胺剂 (标准和高剂量),75,150和300毫克的奥马利祖马布 (OMA),环素和安慰剂.
主要成果:
- 奥马利祖马布300毫克和150毫克的反应率明显高于标准剂量的H1抗胰岛素.
- 与标准和高剂量H1抗胰岛素相比,OMA300mg和150mg都使UAS7和DLQI大幅减少.
- 分析包括39项研究 (37项RCT,2项RWS).
结论:
- 根据风险效益分析,Omalizumab 300mg被确定为慢性疹的最佳药理治疗方法.
- 奥马利祖马布150mg是一种合适的替代品,比H1抗胰岛素和环素更有优势.
- 这些发现支持OMA作为CU管理的高效疗法.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
338
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
338
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
145
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
145
Structure-Activity Relationships and Drug Design
757
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
757
Hazard Ratio
152
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
152
Dose-Response Relationship: Potency and Efficacy
4.5K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
326
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
326


